<DOC>
	<DOCNO>NCT00091715</DOCNO>
	<brief_summary>The present trial investigates possible use oral bosentan , currently approve treatment symptom pulmonary arterial hypertension ( PAH ) Class III IV , patient suffer PAH Class II .</brief_summary>
	<brief_title>Efficacy Safety Oral Bosentan Pulmonary Arterial Hypertension Class II</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>PAH NYHA Class II Significant elevation mean pulmonary arterial pressure Significant elevation pulmonary vascular resistance rest Limited 6minute walk distance PAH secondary portal hypertension , complex congenital heart disease reverse shunt Restrictive obstructive lung disease Significant vasoreactivity Treatments PAH ( within 4 week randomization )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>PPH</keyword>
	<keyword>bosentan</keyword>
	<keyword>early</keyword>
</DOC>